PRIMUS 001
An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer with integrated biomarker evaluation

Pharmacy Initiation Acknowledgement

EudraCT: 2016-004155-67

Principal Investigator:

Centre:

Main Site Contact(s):

1. **Please tick to confirm:**
   - I have received, and viewed the PRIMUS 001 Pharmacy Initiation Presentation (Version 1.1, 21st August 2017) as well as the PRIMUS 001 trial protocol

   Name: ___________________________ (PRINT NAME) Date: __________________

   Signature: ______________________

   Study Role: ______________________

2. **Please tick relevant box below:**
   - I have no further questions on the PRIMUS 001 Study
   - I have the following question(s) on the PRIMUS 001 Study (please provide in space below)

Please return this form to the main PRIMUS 001 Study contact at your site (see above), who will be responsible for forwarding all completed forms and questions collectively to the CRUK CTU Glasgow.